β-Thalassemia and renal complications. A narrative review of pathophysiologic mechanisms

Christos Demosthenous(G. Papanikolaou General Hospital), Efthymia Vlachaki(Senologic Hellenic Society), Vassilios Perifanis(AHEPA University Hospital), Perla Eleftheriou(University College London), Pantelis Sarafidis(Ippokrateio General Hospital of Thessaloniki), Chrysa Apostolou(Hippocration General Hospital)
Integrative Molecular Medicine
January 1, 2018
10.15761/imm.1000340
Cited by 10

Related Papers

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
|The Lancet|2010|518
The systemic nature of CKD
|Nature Reviews Nephrology|2017|438
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association
|Cardiovascular Research|2023|312
Lipid management in patients with chronic kidney disease
|Nature Reviews Nephrology|2018|275